Jamie Justice and Senolytics
Jamie Justice's geroscience work on biomarkers and clinical trial design connects her to both the D+Q nonhuman-primate senolytic trial and the first-in-human senolytics study, placing her at the boundary between preclinical signal and human evidence.
Six months of monthly dasatinib plus quercetin in middle-aged primates cut senescence-marker gene expression in adipose tissue and lowered circulating PAI-1 and MMP-9 (inflammation-linked senescence biomarkers). Immune profiles shifted toward anti-inflammatory, microbial-translocation biomarkers dropped, and blood urea nitrogen (a kidney function readout) improved. Safety held over that window. The authors stated the next step plainly: large controlled trials in older patients.
Jamie Justice is Executive Vice President of the Health Domain at XPRIZE (an international prize foundation) and adjunct professor at Wake Forest University School of Medicine. Her focus is biomarkers and clinical trial design in geroscience (the study of aging biology in clinical context). Her work spans the D+Q primate data and the first-in-human study of senolytics, drugs that selectively kill senescent cells.
The primate data give the senolytic class a real signal. Whether that translates to large controlled human trials remains open.
The edge is substantiated by two distinct pieces of evidence (NHP trial and first-in-human study) rather than a single taxonomic tag, and Justice's role as a clinical trial methodologist rather than a cell-biology researcher gives the connection a meaningful functional angle: she works the measurement and design problem that separates primate data from a powered human trial.